SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
AssigneeJansfat Biotechnology Co., Ltd.
InventorIng-Jun Chen
Life of this patent
Estimating the term…
Abstract
The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed in the present invention are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress because of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction.
Claims19
A method for inhibiting a disorder caused by oxidative stress in a subject, comprises a step of:
- administering to the subject suffering the disorder an effective amount of a composition comprises an ingredient being one of an SAA derivatives compound and an SAA complex compounds, wherein:
- the SAA derivatives compound is represented by formula I,
- the SAA complex compounds is represented by formula II,
- Rm is one selected from a group consisting of a first hydrogen, a first C1-C6 alkyl group, a first C1-C6 alkoxyl group and a 3-membered to 8-membered ring, and either one of R1 and Ra is classified into one of a category I and a category II, and wherein:
- in category I, R1 is one selected from a group consisting of a second hydrogen, a first halogen, a second C1-C6 alkyl group, a first C1-C5 alkoxyl group:
- and
- a first benzene ring having one or more substitute group selected from a second C1-C5 alkoxyl group, a first nitro group, a second halogen, a halogen substitute C1-C5 alkoxyl group and a halogen substitute C1-C6 alkyl group, and Ra is a xanthine group having a substitute of a fourth C1-C5 alkyl group, a third C1-C5 alkoxyl group and a third halogen.
- in category II, R1 is one of a second benzene ring having a substitute being one of a fourth C1-C5 alkoxyl group and a sulfonyl phenyl group and a heterocyclic ring having a substitute being one of a second C1-C6 alkoxyl group and a third C1-C6 alkyl group, and Ra is one selected from a group consisting of a third hydrogen, a second halogen, an amino group, a second nitro group, a second C1-C5 alkyl group and a fifth C1-C5 alkoxyl group,
- the heterocyclic ring is one selected from a group consisting of pyrazolo, pyrimidin, imidazo, pyrollidinyl, triazin and a fused ring having at least one selected from the group consisting of pyrazolo, pyrimidin, pyrollidinyl, imidazo and triazin, −RX is a carboxylic group having a negative charge, and the carboxylic group is donated from one selected from a group consisting of a plant acid, a substituted-sulfonic acids, a oxygen-containing acid (oxyacid), a non-steroid anti-inflammatory (NSAIDs), an anti-asthmatic drug, sodium carboxymethylcellulose, a γ-polyglutamic acid derivatives, a biodegradable polymers and a combination thereof.
A method for inhibiting a disorder caused by oxidative stress in a subject, comprises steps of:
- administering to the subject suffering the disorder an effective amount of a composition comprises an ingredient being one selected from a group consisting of an SAA derivatives, an SAAX derivatives, an SPAAX derivatives, an SPAAS derivatives compound and a combination thereof;
- and
- administering to the subject an additional co-active compound having a carboxylic group.
Dependencies are inferred from the claim text.